啟明醫療(02500.HK):上市後研發無大變化 日後領域或細分化
啟明醫療(02500.HK)總經理訾振軍出席上市儀式後表示,公司本來就是A+H股的結構,屬中外合資企業,被問及近日香港局勢會否對公司股價有影響,他表示公司立足於自我,會將業務做得更好,又相信香港國際金融中心地位,認為經歷過時代考驗所以對香港市場充滿信心。
被問及產品商業化的進程,他指出公司不同的產品線一直處於動態的發展過程,有些已經獲批,有些則正在等候審批,而旗下產品亦不斷處於研發、審批、商業化的過程。至於上市後研發投入方面,他指出公司的產品線經多年佈局,會分階段逐步實行,相信在這方面不會有太大變化,但可能會在自己的領域內細分化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.